NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free ESLA Stock Alerts $1.08 +0.05 (+4.85%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$1.05▼$1.0850-Day Range$0.98▼$1.2652-Week Range$0.86▼$33.00Volume1,127 shsAverage Volume36,027 shsMarket Capitalization$39.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestSocial Media Get Estrella Immunopharma alerts: Email Address Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Estrella ImmunopharmaEstrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Read More ESLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESLA Stock News HeadlinesMarch 7, 2024 | finance.yahoo.comEntheon Biomedical Corp. (ENTBD)February 1, 2024 | msn.comEstrella Immunopharma Approves $1 Million Stock Buyback ProgramMay 8, 2024 | InvestorPlace (Ad)$21,000 in profits in six weeks? On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.January 17, 2024 | msn.comWhy DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving PremarketNovember 23, 2023 | uk.investing.comEstrella Immunopharma Inc (ESLA)November 3, 2023 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLA)November 1, 2023 | morningstar.comEstrella Immunopharma Inc ESLAOctober 20, 2023 | finance.yahoo.comWe Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business GrowthSee More Headlines Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/08/2024Next Earnings (Estimated)5/08/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ESLA CUSIPN/A CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.59% Return on Assets-22.64% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($8.27) per share Price / Book-0.13Miscellaneous Outstanding Shares36,610,000Free Float16,438,000Market Cap$39.54 million OptionableNot Optionable Beta0.19 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Cheng Liu Ph.D. (Age 57)CEO, President & Director Jiandong XuChief Financial OfficerKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSQuince TherapeuticsNASDAQ:QNCXOKYO PharmaNASDAQ:OKYODyadic InternationalNASDAQ:DYAIAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInstitutional OwnershipATW Spac Management LLCBought 40,000 shares on 2/13/2024Ownership: 0.114%View All Institutional Transactions ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed in 2024? Estrella Immunopharma's stock was trading at $1.11 at the start of the year. Since then, ESLA stock has decreased by 2.7% and is now trading at $1.08. View the best growth stocks for 2024 here. Are investors shorting Estrella Immunopharma? Estrella Immunopharma saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 4,600 shares, a decrease of 41.8% from the March 31st total of 7,900 shares. Based on an average daily trading volume, of 30,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's shares are sold short. View Estrella Immunopharma's Short Interest. When is Estrella Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ESLA earnings forecast. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESLA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
